Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients

J Antimicrob Chemother. 2014 Sep;69(9):2586-8. doi: 10.1093/jac/dku142. Epub 2014 May 8.

Authors

A Calcagno¹, S Nozza², M Simiele³, M G Milia⁴, S Chiappetta², A D'Avolio³, V Ghisetti⁴, A Lazzarin², G Di Perri³, S Bonora³

Affiliations

¹ Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy [email protected].
² Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.
³ Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy.
⁴ Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy.

PMID: 24812593
DOI: 10.1093/jac/dku142

No abstract available

Keywords: HIV RNA; NRTI-sparing; dual regimen; genital; seminal fluid.

Publication types

Letter

MeSH terms

Adult
Anti-HIV Agents / administration & dosage
Anti-HIV Agents / pharmacokinetics*
Cyclohexanes / administration & dosage
Cyclohexanes / pharmacokinetics*
HIV Infections / drug therapy*
Humans
Lopinavir / administration & dosage
Lopinavir / pharmacokinetics*
Male
Maraviroc
Middle Aged
Plasma / chemistry
Ritonavir / administration & dosage
Ritonavir / pharmacokinetics*
Semen / chemistry*
Triazoles / administration & dosage
Triazoles / pharmacokinetics*

Substances

Anti-HIV Agents
Cyclohexanes
Triazoles
Lopinavir
Maraviroc
Ritonavir